Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AT177
- Development stage
- Unknown
- Lead developer
- Azora Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AT177 is an oral, small molecule agonist of the aryl hydrocarbon receptor (AhR) currently in Phase 1 clinical development for the treatment of ulcerative colitis. Developed by Azora Therapeutics, a spin-out from Stanford University's SPARK program, AT177 is designed to provide the therapeutic benefits of AhR activation—such as improved intestinal barrier function and immune regulation—while being specifically formulated to minimize systemic exposure. This gut-targeted approach aims to replicate the efficacy seen with botanical extracts like indigo naturalis in treatment-refractory patients while improving the safety profile for chronic use in inflammatory bowel diseases.
02
Targets
AHR (Aryl hydrocarbon receptor)
Beyond the preview
Go deeper on AT177.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AT177.